Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single-Ascending and Multiple-Ascending Doses of the Influenza A Virus Replication Inhibitor CC-42344

Trial Profile

A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single-Ascending and Multiple-Ascending Doses of the Influenza A Virus Replication Inhibitor CC-42344

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CC 42344 (Primary)
  • Indications Influenza A virus H1N1 subtype; Influenza A virus infections
  • Focus Adverse reactions; First in man
  • Sponsors Cocrystal Pharma Inc
  • Most Recent Events

    • 19 Mar 2024 Results published in the Cocrystal Pharma Inc Media Release.
    • 29 May 2023 Number of arms changed from 7 to 9. Experimental: MAD cohort 2D and Experimental: MAD cohort 2E added to study protocol. Time frame changed from Day 1 to Day 21 to Day 1 to 7 days after last dose.
    • 04 May 2023 According to a Cocrystal Pharma Inc media release, results from this trial were presented at the 7th Annual International Society for Influenza and Other Respiratory Virus Diseases (ISIRV) Antiviral Group Conference 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top